Sign in
NVO vs. LLY Stock Comparison
Updated: Jun 5, 2026
Compare Novo Nordisk A/S (NVO) and Eli Lilly and Company (LLY) stocks across key metrics, including the price chart below of performance and returns, as well as a side-by-side comparison of fundamentals, valuation, dividends and more. Check out our ETF comparison tool to compare ETFs instead.
Select stocks
NVO
$42.96
LLY
$1,131.42
| Add stock | Add stock | Add stock | |||
|---|---|---|---|---|---|
Basics | |||||
| Name | Novo Nordisk A/S | Eli Lilly and Company | |||
| Price | $42.96 | $1,131.42 | |||
| Sector | Health care | Health care | |||
| Market cap | large / 190,904,859 | large / 1,065,504,602 | |||
| Beta | 0.35 | 0.48 | |||
Dividends | |||||
| Dividend | $1.81 | $6.46 | |||
| Yield | 4.20% | 0.57% | |||
| Frequency | Bi-annually | Quarterly | |||
| Payout ratio | 42.28% | 22.96% | |||
| Dividend CAGR (3y) | 27.11% | 15.25% | |||
| Dividend CAGR (5y) | |||||
| Dividend CAGR (10y) | |||||
Dividend safety score | |||||
| Overall score | |||||
| Forward payout ratio | |||||
| Payout ratio/FCF | |||||
| Dividend CAGR (3y) | |||||
| Revenue CAGR (3y) | |||||
| Debt/EBITDA | |||||
| Debt/Equity | |||||
Valuation | |||||
| P/E | 10.06x | 40.22x | |||
| P/S | 3.37x | 12.73x | |||
| P/B | 5.36x | 29.72x | |||
| P/CF | 8.73x | 46.91x | |||
| P/FCF | 18.50x | 92.49x | |||
| PEG ratio | -1.31x | 3.13x | |||
| EV/EBITDA | 5.82x | 28.44x | |||
Fundamentals | |||||
| Gross margin | 80.98% | 83.79% | |||
| Operating margin | 41.36% | 45.56% | |||
| Pretax margin | 42.24% | 39.48% | |||
| Net margin | 33.14% | 31.66% | |||
| Tax rate | 21.53% | 19.79% | |||
| ROE | 60.96% | 97.85% | |||
| ROA | 18.82% | 18.35% | |||
| Interest coverage | 19.57x | 37.34x |
| Add stock | Add stock | Add stock | |||||||
|---|---|---|---|---|---|---|---|---|---|
Basics | |||||||||
| Name | Novo Nordisk A/S | Eli Lilly and Company | |||||||
| Price | $42.96 | $1,131.42 | |||||||
| Sector | Health care | Health care | |||||||
| Market cap | large / 190,904,859 | large / 1,065,504,602 | |||||||
| Beta | 0.35 | 0.48 | |||||||
Dividends | |||||||||
| Dividend | $1.81 | $6.46 | |||||||
| Yield | 4.20% | 0.57% | |||||||
| Frequency | Bi-annually | Quarterly | |||||||
| Payout ratio | 42.28% | 22.96% | |||||||
| Dividend CAGR (3y) | 27.11% | 15.25% | |||||||
| Dividend CAGR (5y) | |||||||||
| Dividend CAGR (10y) | |||||||||
Dividend safety score | |||||||||
| Overall score | |||||||||
| Forward payout ratio | |||||||||
| Payout ratio/FCF | |||||||||
| Dividend CAGR (3y) | |||||||||
| Revenue CAGR (3y) | |||||||||
| Debt/EBITDA | |||||||||
| Debt/Equity | |||||||||
Valuation | |||||||||
| P/E | 10.06x | 40.22x | |||||||
| P/S | 3.37x | 12.73x | |||||||
| P/B | 5.36x | 29.72x | |||||||
| P/CF | 8.73x | 46.91x | |||||||
| P/FCF | 18.50x | 92.49x | |||||||
| PEG ratio | -1.31x | 3.13x | |||||||
| EV/EBITDA | 5.82x | 28.44x | |||||||
Fundamentals | |||||||||
| Gross margin | 80.98% | 83.79% | |||||||
| Operating margin | 41.36% | 45.56% | |||||||
| Pretax margin | 42.24% | 39.48% | |||||||
| Net margin | 33.14% | 31.66% | |||||||
| Tax rate | 21.53% | 19.79% | |||||||
| ROE | 60.96% | 97.85% | |||||||
| ROA | 18.82% | 18.35% | |||||||
| Interest coverage | 19.57x | 37.34x | |||||||
Report issue